Read up on our latest news

Featured Story

Mirvie Founders
Mirvie Raises $60 Million For Blood Test To Predict Pregnancy Complications
May 17, 2022
The company announced it raised $60 million in Series B funding led by Decheng Capital. BlackRock, Foresite Capital, General Catalyst, GV, Khosla Ventures, and Mayfield participated in the round. Olympic runner Allyson Felix, whose daughter was born eight weeks early due to preeclampsia complications, also invested in the round. The company has raised a total of $90 million to date.
Read more
Stst Logo
Mirvie Raises $60 Million For Blood Test To Predict Pregnancy Complications
May 17, 2022
The company announced it raised $60 million in Series B funding led by Decheng Capital. BlackRock, Foresite Capital, General Catalyst, GV, Khosla Ventures, and Mayfield participated in the round. Olympic runner Allyson Felix, whose daughter was born eight weeks early due to preeclampsia complications, also invested in the round. The company has raised a total of $90 million to date.
Read more
Mirvie Founders

Media Coverage

press logo
Breakthrough study backs Mirvie blood test to predict preeclampsia months before symptoms
April 8, 2025
Results from a breakthrough study published today in Nature Communications reveal new advances in the biological understanding of hypertensive disorders of pregnancy (HDP), including preeclampsia
Read more
press logo
Blood test maker Mirvie ushers in Preeclampsia Awareness Month with prevention toolkit
July 3, 2024
The “Preeclampsia Prevention is Possible” campaign website includes a collection of downloadable resources aimed mainly at helping clinicians better recognize the early signs of the condition and shape their care plans for high-risk patients.
Read more
press logo
Research advances biological understanding of hypertensive disorders of pregnancy
April 8, 2025
Diagnostics company Mirvie has announced the results of a breakthrough study that reveals new advances in the biological understanding of hypertensive disorders of pregnancy (HDP), including preeclampsia – a leading cause of maternal morbidity and mortality as well as preterm birth.
Read more
press logo
Patients interested in learning about preeclampsia risk
March 27, 2024
The majority of childbearing-age people would value predictive testing for preeclampsia and report they would act on this information, according to a study in BMC Pregnancy and Childbirth.
Read more
press logo
Mirvie Validates Blood Test to Predict Preeclampsia Months Before Symptoms
April 8, 2025
The validation results show the blood test can identify 91% of pregnancies that will develop preterm preeclampsia in women aged 35+ without pre-existing high-risk conditions, months ahead of symptoms.
Read more
press logo
The future of pregnancy health: prediction and prevention
March 27, 2024
If doctors had better tools to understand each pregnancy’s biology, they could then help moms and babies achieve better outcomes.
Read more
press logo
How science is individualizing pregnancy risks
March 10, 2025
Each pregnancy has its own unique biology that can power personalized care.
Read more
press logo
Research highlights strong demand for data on personalized risk of preeclampsia
March 19, 2024
New research from Mirvie highlights significant demand for predictive testing for pregnancy complications like preeclampsia.
Read more
press logo
Mirvie's RNA platform revolutionizes detection of fetal growth restriction
February 4, 2025
Discover how Mirvie’s RNA platform uses a simple blood test to detect fetal growth restriction early in pregnancy, allowing for proactive interventions and improved outcomes for mothers and babies.
Read more
press logo
Preeclampsia & other pregnancy complications: What women need to know
April 2, 2024
Dr. Alison Cowan of Mirvie shares the facts behind common pregnancy complications and how women can advocate for themselves during pregnancy.
Read more
A personalized window
into pregnancy health.
650-741-6510
651 Gateway Boulevard, Suite 1200
South San Francisco, California 94080
References
Terms of Service
Privacy Policy
©2025 Mirvie, Inc. All rights reserved.